SE9002550D0 - Heparinfragment - Google Patents

Heparinfragment

Info

Publication number
SE9002550D0
SE9002550D0 SE9002550A SE9002550A SE9002550D0 SE 9002550 D0 SE9002550 D0 SE 9002550D0 SE 9002550 A SE9002550 A SE 9002550A SE 9002550 A SE9002550 A SE 9002550A SE 9002550 D0 SE9002550 D0 SE 9002550D0
Authority
SE
Sweden
Prior art keywords
heparin
regardless
activity
relates
bleeding time
Prior art date
Application number
SE9002550A
Other languages
English (en)
Inventor
H-P T Ekre
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE9002550A priority Critical patent/SE9002550D0/sv
Publication of SE9002550D0 publication Critical patent/SE9002550D0/sv
Priority to PCT/SE1991/000502 priority patent/WO1992002232A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SE9002550A 1990-08-01 1990-08-01 Heparinfragment SE9002550D0 (sv)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE9002550A SE9002550D0 (sv) 1990-08-01 1990-08-01 Heparinfragment
PCT/SE1991/000502 WO1992002232A1 (en) 1990-08-01 1991-07-19 Heparin fragment showing complement inhibition activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002550A SE9002550D0 (sv) 1990-08-01 1990-08-01 Heparinfragment

Publications (1)

Publication Number Publication Date
SE9002550D0 true SE9002550D0 (sv) 1990-08-01

Family

ID=20380076

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9002550A SE9002550D0 (sv) 1990-08-01 1990-08-01 Heparinfragment

Country Status (2)

Country Link
SE (1) SE9002550D0 (sv)
WO (1) WO1992002232A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CA2795360A1 (en) 2010-04-16 2011-10-20 Momenta Pharmaceuticals, Inc. Tissue targeting
EP2582355A2 (en) 2010-06-17 2013-04-24 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
LT2794665T (lt) 2011-12-19 2017-12-27 Dilafor Ab Neantikoaguliaciniai glikozaminoglikanai, apimantys pasikartojantį disacharido vienetą, ir jų medicininis panaudojimas
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation

Also Published As

Publication number Publication date
WO1992002232A1 (en) 1992-02-20

Similar Documents

Publication Publication Date Title
SE9002550D0 (sv) Heparinfragment
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
DE3268075D1 (en) Preparation for treating outer skin wounds and process for manufacturing said preparation
PT82724B (pt) Processo para a preparacao de derivados de difluoro cetona-peptideos e de uma composicao farmaceutica que os contem
IL69930A0 (en) Oral mopidamol preparations and their production
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
UA45942A (uk) 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
DK0396184T3 (da) Anvendelse af ketoconazol og et retinoid til behandling af acne vulgaris
FI821804A0 (fi) Polysackarider baserade pao nytt anti-tromboticum, foerfarande foer dess framstaellning och farmaceutiska kompositioner
NO872675L (no) Middel for hemning av avstoetning av transplanterte organer
SE8505488D0 (sv) Isosilybinfri silibinin
EP0333243A3 (en) Sulphated k5 antigen and sulphated k5 antigen fragments
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
ATE187648T1 (de) Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
ATE119781T1 (de) Antikoagulanszubereitung.
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
EP0317933A3 (en) Treatment of fibromyalgia
SU1169655A1 (ru) Способ лечени тромбооблитерирующих заболеваний артерий конечностей
IT1229271B (it) Preparazione medicinale di un estratto delle radici di ortica, urtica kiovensis (rogowicz), suo impiego per il trattamento di tumori e processo di preparazione.
SU929075A1 (ru) Способ лечени контрактуры дюпюптрена
SE8802193D0 (sv) Externally applicable, antiviral pharmaceutical composition accumulating in the skin and process for the preparation of the same
DZ1366A1 (fr) Nouveaux dérivés de la méthoxycarbonyl-2 n,n'-di-(triméthoxybenzoyle) pipérazine, ainsi que leur procédé de préparation.